LON:BTG - BTG Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 840
▲ +1 (0.12%)

This chart shows the closing price for BTG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BTG Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BTG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BTG

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for BTG in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 840.

This chart shows the closing price for BTG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in BTG. This rating has held steady since October 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/20/2018Peel HuntBoost Price TargetHoldGBX 670 ➝ GBX 840
11/20/2018Royal Bank of CanadaReiterated RatingUnderperform
11/14/2018JPMorgan Chase & Co.Boost Price TargetNeutralGBX 650 ➝ GBX 680
11/13/2018Peel HuntReiterated RatingHoldGBX 640 ➝ GBX 670
11/1/2018Peel HuntReiterated RatingHold
10/16/2018Royal Bank of CanadaLower Price TargetUnderperformGBX 510 ➝ GBX 490
10/5/2018JPMorgan Chase & Co.Reiterated RatingNeutral
10/4/2018Shore CapitalReiterated RatingBuy
10/4/2018Numis SecuritiesReiterated RatingBuy
10/4/2018Royal Bank of CanadaReiterated RatingUnderperformGBX 510
10/3/2018Peel HuntReiterated RatingHold
9/24/2018Deutsche Bank AktiengesellschaftReiterated RatingHoldGBX 645
9/17/2018Deutsche Bank AktiengesellschaftReiterated RatingHoldGBX 645
9/7/2018Numis SecuritiesReiterated RatingBuy
9/7/2018Shore CapitalReiterated RatingBuy
9/4/2018Peel HuntReiterated RatingHold
9/4/2018Deutsche Bank AktiengesellschaftReiterated RatingHoldGBX 645
8/21/2018JPMorgan Chase & Co.Reiterated RatingNeutralGBX 650
8/9/2018Peel HuntReiterated RatingHoldGBX 640
8/9/2018Shore CapitalReiterated RatingBuy
8/1/2018Peel HuntReiterated RatingHold
7/19/2018Deutsche Bank AktiengesellschaftReiterated RatingHold
7/18/2018Numis SecuritiesReiterated RatingBuy
7/18/2018Shore CapitalReiterated RatingBuy
7/18/2018Peel HuntReiterated RatingHold
7/3/2018Peel HuntReiterated RatingHold
6/20/2018Royal Bank of CanadaReiterated RatingUnderperformGBX 510
6/15/2018Peel HuntReiterated RatingHoldGBX 640
6/15/2018Shore CapitalReiterated RatingBuy
6/15/2018Numis SecuritiesReiterated RatingBuy
6/13/2018Deutsche Bank AktiengesellschaftReiterated RatingHold
6/5/2018Numis SecuritiesReiterated RatingBuyGBX 840
5/31/2018Peel HuntReiterated RatingHold
5/24/2018Peel HuntLower Price TargetHoldGBX 700 ➝ GBX 640
5/17/2018Deutsche Bank AktiengesellschaftDowngradeHoldGBX 810 ➝ GBX 645
5/16/2018JPMorgan Chase & Co.Lower Price TargetNeutralGBX 680 ➝ GBX 650
5/15/2018Numis SecuritiesReiterated RatingBuyGBX 840
5/15/2018Jefferies Financial GroupBoost Price TargetBuyGBX 775 ➝ GBX 900
5/15/2018Shore CapitalReiterated RatingBuy
5/15/2018Peel HuntReiterated RatingHold
4/6/2018JPMorgan Chase & Co.Lower Price TargetNeutralGBX 750 ➝ GBX 680
4/4/2018Peel HuntReiterated RatingHoldGBX 700
3/26/2018Shore CapitalUpgradeBuy
2/1/2018Numis SecuritiesReiterated RatingBuyGBX 900
2/1/2018Peel HuntReiterated RatingHoldGBX 700
1/24/2018Numis SecuritiesReiterated RatingBuyGBX 900
1/15/2018JPMorgan Chase & Co.Reiterated RatingNeutral
12/8/2017JPMorgan Chase & Co.Reiterated RatingNeutral
12/8/2017Numis SecuritiesReiterated RatingBuyGBX 900
11/22/2017JPMorgan Chase & Co.Lower Price TargetNeutralGBX 750 ➝ GBX 730
11/15/2017JPMorgan Chase & Co.Reiterated RatingNeutral
11/14/2017Peel HuntReiterated RatingHoldGBX 680
11/7/2017Deutsche Bank AktiengesellschaftReiterated RatingBuyGBX 775
11/7/2017JPMorgan Chase & Co.Reiterated RatingNeutral
11/6/2017Peel HuntReiterated RatingHoldGBX 680
10/31/2017Peel HuntReiterated RatingHoldGBX 680
10/18/2017Numis SecuritiesReiterated RatingBuyGBX 900
10/13/2017Deutsche Bank AktiengesellschaftReiterated RatingBuyGBX 775
10/6/2017JPMorgan Chase & Co.Reiterated RatingNeutral
10/6/2017Deutsche Bank AktiengesellschaftReiterated RatingBuyGBX 775
10/5/2017Numis SecuritiesReiterated RatingBuyGBX 900
9/21/2017Deutsche Bank AktiengesellschaftReiterated RatingBuyGBX 775
9/20/2017Peel HuntReiterated RatingHoldGBX 680
9/20/2017Numis SecuritiesReiterated RatingBuyGBX 900
9/18/2017JPMorgan Chase & Co.Reiterated RatingNeutral
8/30/2017Stifel NicolausReiterated RatingBuyGBX 800
8/9/2017Numis SecuritiesReiterated RatingBuyGBX 900
7/13/2017Shore CapitalReiterated Ratingnot rated
7/13/2017Numis SecuritiesReiterated RatingBuyGBX 900
7/4/2017JPMorgan Chase & Co.Reiterated RatingNeutralGBX 790
6/29/2017Numis SecuritiesReiterated RatingBuyGBX 900
6/14/2017Numis SecuritiesReiterated RatingBuyGBX 900
5/23/2017JPMorgan Chase & Co.Reiterated RatingNeutralGBX 750
5/22/2017Numis SecuritiesReiterated RatingBuyGBX 900
5/22/2017Panmure GordonLower Price TargetBuyGBX 809 ➝ GBX 793
5/18/2017Deutsche Bank AktiengesellschaftReiterated RatingBuyGBX 775
5/17/2017JPMorgan Chase & Co.Lower Price TargetNeutralGBX 790 ➝ GBX 750
5/16/2017Numis SecuritiesReiterated RatingBuyGBX 900
5/16/2017Jefferies Financial GroupReiterated RatingBuyGBX 775
5/16/2017Panmure GordonBoost Price TargetBuyGBX 737 ➝ GBX 809
5/16/2017Peel HuntReiterated RatingHoldGBX 630
4/25/2017Numis SecuritiesReiterated RatingBuyGBX 900
4/20/2017Panmure GordonReiterated RatingBuyGBX 737
4/7/2017JPMorgan Chase & Co.Reiterated RatingNeutralGBX 790
4/6/2017InvestecReiterated RatingBuyGBX 720
4/4/2017Numis SecuritiesReiterated RatingBuyGBX 900
4/4/2017Stifel NicolausReiterated RatingBuyGBX 725
3/28/2017JPMorgan Chase & Co.Reiterated RatingNeutralGBX 790
3/21/2017JPMorgan Chase & Co.Reiterated RatingNeutralGBX 790
2/24/2017Peel HuntReiterated RatingHoldGBX 630
2/16/2017Numis SecuritiesReiterated RatingBuyGBX 900
1/26/2017Panmure GordonReiterated RatingBuyGBX 737
1/26/2017Deutsche Bank AktiengesellschaftLower Price TargetBuyGBX 800 ➝ GBX 775
1/25/2017Numis SecuritiesReiterated RatingBuyGBX 900
1/25/2017Peel HuntInitiated CoverageHoldGBX 630
1/24/2017Jefferies Financial GroupLower Price TargetBuyGBX 860 ➝ GBX 775
1/17/2017JPMorgan Chase & Co.Reiterated RatingNeutral
1/5/2017Panmure GordonReiterated RatingBuyGBX 737
1/5/2017Jefferies Financial GroupReiterated RatingBuyGBX 860
1/4/2017JPMorgan Chase & Co.Lower Price TargetNeutralGBX 800 ➝ GBX 790
12/6/2016JPMorgan Chase & Co.Reiterated RatingNeutralGBX 800
11/16/2016Jefferies Financial GroupReiterated RatingBuyGBX 860
11/16/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyGBX 850 ➝ GBX 865
11/16/2016JPMorgan Chase & Co.Lower Price TargetNeutralGBX 830 ➝ GBX 800
11/15/2016Numis SecuritiesReiterated RatingBuyGBX 900
11/3/2016Stifel NicolausUpgradeBuyGBX 640 ➝ GBX 725
11/1/2016Royal Bank of CanadaDowngradeSector PerformerGBX 910 ➝ GBX 790
10/26/2016Deutsche Bank AktiengesellschaftBoost Price TargetBuyGBX 840 ➝ GBX 865
10/17/2016Numis SecuritiesUpgradeBuyGBX 900
10/7/2016Deutsche Bank AktiengesellschaftReiterated RatingBuy
10/7/2016JPMorgan Chase & Co.Boost Price TargetNeutralGBX 790 ➝ GBX 830
10/6/2016Stifel NicolausReiterated RatingHoldGBX 640
10/6/2016Numis SecuritiesReiterated RatingHoldGBX 737
9/9/2016JPMorgan Chase & Co.Reiterated RatingNeutral
9/8/2016Deutsche Bank AktiengesellschaftReiterated RatingBuy
8/23/2016JPMorgan Chase & Co.Reiterated RatingNeutralGBX 790
8/16/2016JPMorgan Chase & Co.Reiterated RatingNeutralGBX 790
7/18/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyGBX 840
7/15/2016JPMorgan Chase & Co.Lower Price TargetNeutralGBX 800 ➝ GBX 790
7/15/2016Jefferies Financial GroupReiterated RatingBuyGBX 860
7/14/2016Stifel NicolausDowngradeHold
7/14/2016Numis SecuritiesReiterated RatingHoldGBX 737
7/12/2016Deutsche Bank AktiengesellschaftBoost Price TargetBuyGBX 740 ➝ GBX 840
6/29/2016Jefferies Financial GroupBoost Price TargetBuyGBX 840 ➝ GBX 860
6/24/2016Stifel NicolausReiterated RatingBuy
6/24/2016Numis SecuritiesReiterated RatingHoldGBX 654
6/24/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyGBX 740
(Data available from 6/22/2016 forward)
BTG logo
BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications. This segment also provides interventional vascular products consisting of EKOS system, an ultrasonic catheter drug delivery device used in the treatment of blood clots; Varithena for the treatment of varicose veins; and PneumRx Coil for the treatment of emphysema, a debilitating lung disease. The Pharmaceuticals segment offers antidote products, such as CroFab for the treatment of crotalid snake envenomations; DigiFab for the treatment of digoxin toxicity; and Voraxaze for high-dose methotrexate toxicity. The Licensing segment provides Zytiga for treatment of prostate cancer; Two-Part Hip Cup; and Lemtrada. The company also manufactures and commercializes therapeutic ultrasound devices, and roxwood systems, as well as develops venous thrombus management devices. The company was formerly known as British Technology Group International plc and changed its name to BTG plc in March 1995. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: GBX 840
Low: 840
High: 840

50 Day Range

MA: GBX 839.98
Low: 839
High: 840

52 Week Range

Now: GBX 840
Low: 512.50
High: 853

Volume

271,742 shs

Average Volume

960,389 shs

Market Capitalization

£3.26 billion

P/E Ratio

29.47

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of BTG?

The following sell-side analysts have issued stock ratings on BTG in the last twelve months:
View the latest analyst ratings for BTG.

What is the current price target for BTG?

0 Wall Street analysts have set twelve-month price targets for BTG in the last year. has the lowest price target set, forecasting a price of £100,000 for BTG in the next year.
View the latest price targets for BTG.

What is the current consensus analyst rating for BTG?

BTG currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for BTG.

What other companies compete with BTG?

How do I contact BTG's investor relations team?

BTG's physical mailing address is 5 Fleet Place, LONDON, EC4M 7RD, United Kingdom. The company's listed phone number is +44-20-75750000. The official website for BTG is www.btgplc.com.